IRIDEX Corporation: stock overview

IRIXNASDAQHealthcare · Electromedical & Electrotherapeutic Apparatus

Price

$0.69

November 13, 2026Market cap $12M

What Ploutos Investor adds for IRIDEX

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 26% since Aug 18, 2026, when the 10-Q these figures come from was filed ($0.93 then, $0.69 on Nov 13, 2026). The figures date from before that move.10-Q

In short

IRIDEX had revenue of $52M over the last 12 months and a net loss of $3.5M. Revenue grew by 7.7% a year on average over the last 5 years. It holds more cash than debt, by $885.0K. It pays no dividend.

From its SEC filings (latest fiscal year to January 3, 2026) and the price of November 13, 2026.

Its SEC filings
Market cap
$12M
17.31M shares
P/E
–
Revenue, 12 months
$52M
+7.7% a year over 5 years
Net margin
-6.9%
FY2025: -8.4%, above 37% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2023–FY2025 fiscal years

+0.8% a year over 2 years

  • FY2025Jan 3, 202610-K
    Revenue$53M
  • FY2024Dec 28, 202410-K
    Revenue$49M
  • FY2023Dec 30, 202310-K
    Revenue$52M

Fiscal years in figures

IRIX's revenue, profit, cash flow and dividend with each year-end price, from FY2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $28M
$12M
Enterprise value 
$11M
P/E 
–
EV / EBIT 
–
EV / Revenue 
0.2
P/B 3-year median: 4.8
3.3
FCF yield 3-year median: -15.0%
–
Earnings yield 3-year median: -22.2%
–

Profitability

Gross margin 
35.9%
Operating margin 
-5.4%
Net margin 3-year median: -18.3%
-6.9%
ROIC 
-24.7%
ROIC, 5-year average 
-60.7%
ROE 
-73.8%

Growth

Revenue, yearly change 
+8.2%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+7.7%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$4.7M
Total debt 
$4.0M
Of which operating leases 
$218.0K
Net cash 
$885.0K
Net debt / EBITDA 
–
Interest cover 
-47.9x
Current ratio 
1.82

Balance sheet of July 4, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+3.1%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).

Gross margin

36.5%

Above 18% of the 161 companies in its industry, and 50% of all.

Operating margin

-4.9%

Above 41% of the 186 companies in its industry, and 25% of all.

Net margin

-8.4%

Above 37% of the 189 companies in its industry, and 20% of all.

ROA

-15.2%

Above 24% of the 190 companies in its industry, and 11% of all.

Revenue growth

8.2%

Above 51% of the 186 companies in its industry, and 56% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
IRIDEX CORP
Exchange
NASDAQ
Industry (SIC)
3845 · Electromedical & Electrotherapeutic Apparatus
Fiscal year ends
January 3
Latest annual report
January 3, 2026
Reporting currency
USD
Shares
17.31M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do IRIDEX's filings show?

These are IRIDEX's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about IRIX

Didn't find what you were looking for?

Ask us
What is IRIX's market cap?

IRIDEX Corporation's market cap is $12M, at a price of $0.69 on November 13, 2026 and 17.31M shares.

How much revenue does IRIX have?

IRIDEX had revenue of $52M over the last 12 months. Over the last 5 years it changed by +7.7% a year on average.

Does IRIX pay a dividend?

No. IRIDEX paid no regular dividend over the last 12 months.

Where do the figures come from?

From IRIDEX Corporation's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.